Announcement no. 27

Interim Financial Statements for the first half of 2007

During the first six months of 2007, the BioPorto Group has experienced positive development in line with expectations. The most important events and results during the first half of 2007 thus include (comparative figures for the first half of 2006 are indicated in brackets):

·The revenue increased in the first half of 2007 by 51 per cent to DKK 3.7 million (DKK 2.5 million).

·Operating profit or loss was DKK -6.0 million (DKK -6.9 million).

·Income for the period was DKK -6.8 million (DKK -7.3 million), corresponding to a reduction of the loss of approx. 7 per cent.

·The Company´s cash amounted to DKK 36.4 million on June 30, 2007 relative to DKK -4.0 million on December 31, 2006. The reason for the significant increase in cash flow is primarily the capital increase effected during the period with net proceeds of DKK 47 million.

·Following the capital injection and conversion of convertible bonds, BioPorto has a positive shareholders´ equity of DKK 36.8 million.

·BioPorto´s activities in the NGAL field include launch of antibodies against rat NGAL, submission of another patent application, negotiations on the Company´s NGAL patent rights and licenses thereto. In this connection, the Company has made an effort to ensure the highest possible level of protection of the NGAL patent claims already submitted.

·In order to strengthen its sales and marketing activities, the Company has employed a product manager for the NGAL field. In addition, two product managers were hired in August to strengthen the Company´s product portfolio.

·At the extraordinary general meeting on July 18, three new members were elected to BioPorto´s Board of Directors, which has appointed Carsten Lønfeldt as new Chairman of the Board. The Board now consists of Carsten Lønfeldt, Ejner Bech Jensen, Niels Tækker Foged and Peter Nordkild.

Expectations for the 2007 financial year

·The expectations for the sale of the Company´s antibodies and diagnostic kits are specified. Thus the revenue for 2007 is expected to increase by 40-50 per cent to approx. DKK 8 million (DKK 5.6 million).

·The expectations for the net income or loss for the period are based on the expectation that the increased revenue will be accompanied by increasing costs, primarily related to the expected expansion of sales and marketing activities. Consequently, a loss of DKK -15.0 million is expected for the year.

·Any license income for the Company´s NGAL patent rights has not been included in the expectations. A separate company announcement will be issued via OMX Nordic Exchange once the Company is able to assess the amount and timing of any license income more precisely.

See PDF in right hand menu for the full statement